Roya Abbasi Natajomrani, D. Qujeq, R. Hajihosseini, V. Hosseini
{"title":"结直肠癌患者的血脂和类固醇激素水平","authors":"Roya Abbasi Natajomrani, D. Qujeq, R. Hajihosseini, V. Hosseini","doi":"10.5812/hmj.102085","DOIUrl":null,"url":null,"abstract":"Background: Lipids are usually crucial to develop tumors, and dyslipidemia is correlated with the high chance of colon and colorectal cancer (CRC). Steroid hormones such as estrogen and progesterone can decrease the risk of colorectal cancer development. Objectives: The present study aimed to compare the serum levels of lipid profile and steroid hormones in patients with CRC and healthy controls. Methods: The present study included 40 consecutive adult patients with CRC in the Mazandaran Cancer Center, Sari, Iran, between 2017 and 2020.The diagnosis of CRC was evaluated based on colonoscopy with biopsy and CT scan. Also, the diagnosis of CRC was based on NCCN clinical practice guidelines in oncology. Blood samples were taken before treatment during routine testing. A 5 mL of peripheral blood was collected from each patient. All patients signed the written consent for the study. Also, a total of 40 healthy subjects were selected as healthy controls from the same area during a routine physical examination, which was also confirmed by screening colonoscopy and pathology. Serum TCh and TG levels were quantitatively determined by the colorimetric method. LDL-C and HDL-C were determined by the turbidimetric immunoassay. Steroid hormones were quantitatively determined by the Enzyme-linked immunosorbent assay (ELISA) according to the reagent manufacturer’s instruction. To analyze data, the SPSS software package (version 21) was applied. Results: Among all the indicators studied, the (mean ± SD) of testosterone, FSH and LH levels was higher (1.85 ± 1.63 ng/ml, 15.35 ± 0.13mIU/l, 12.42 ± 0.12.16mIU/ml) in patients with CRC than (mean ± SD) healthy controls (0.40 ± 0.21ng/ml, 6.27 ± 0.50mIU/ml, 2.89 ± 0.20mIU/ml, P < 0.05), respectively. Also, the results in subgroups showed that the mean testosterone (0.91 ± 1.2ng/l), FSH (19.11 ± 16mIU/ml), LH (14.49 ± 14mIU/ml) levels in the woman patients with CRC was higher than healthy female controls and had more statistical significance (p = 0.02, 0.00, 0.00), respectively. The area under the AUC cure (Figure 1) of the testosterone, FSH, and LH indicates positive test (0.670, 0.726 and 0.775). Conclusions: Changes in the levels of steroid hormones and lipids could correlate with the elevated chance of CRC. Therefore, assessment of multiple markers might overcome and provide better judgment in patients with CRC.","PeriodicalId":271947,"journal":{"name":"Hormozgan Medical Journal","volume":"18 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum Lipid Profile and Steroid Hormone Levels in Patients with Colorectal Cancer\",\"authors\":\"Roya Abbasi Natajomrani, D. Qujeq, R. Hajihosseini, V. Hosseini\",\"doi\":\"10.5812/hmj.102085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Lipids are usually crucial to develop tumors, and dyslipidemia is correlated with the high chance of colon and colorectal cancer (CRC). Steroid hormones such as estrogen and progesterone can decrease the risk of colorectal cancer development. Objectives: The present study aimed to compare the serum levels of lipid profile and steroid hormones in patients with CRC and healthy controls. Methods: The present study included 40 consecutive adult patients with CRC in the Mazandaran Cancer Center, Sari, Iran, between 2017 and 2020.The diagnosis of CRC was evaluated based on colonoscopy with biopsy and CT scan. Also, the diagnosis of CRC was based on NCCN clinical practice guidelines in oncology. Blood samples were taken before treatment during routine testing. A 5 mL of peripheral blood was collected from each patient. All patients signed the written consent for the study. Also, a total of 40 healthy subjects were selected as healthy controls from the same area during a routine physical examination, which was also confirmed by screening colonoscopy and pathology. Serum TCh and TG levels were quantitatively determined by the colorimetric method. LDL-C and HDL-C were determined by the turbidimetric immunoassay. Steroid hormones were quantitatively determined by the Enzyme-linked immunosorbent assay (ELISA) according to the reagent manufacturer’s instruction. To analyze data, the SPSS software package (version 21) was applied. Results: Among all the indicators studied, the (mean ± SD) of testosterone, FSH and LH levels was higher (1.85 ± 1.63 ng/ml, 15.35 ± 0.13mIU/l, 12.42 ± 0.12.16mIU/ml) in patients with CRC than (mean ± SD) healthy controls (0.40 ± 0.21ng/ml, 6.27 ± 0.50mIU/ml, 2.89 ± 0.20mIU/ml, P < 0.05), respectively. Also, the results in subgroups showed that the mean testosterone (0.91 ± 1.2ng/l), FSH (19.11 ± 16mIU/ml), LH (14.49 ± 14mIU/ml) levels in the woman patients with CRC was higher than healthy female controls and had more statistical significance (p = 0.02, 0.00, 0.00), respectively. The area under the AUC cure (Figure 1) of the testosterone, FSH, and LH indicates positive test (0.670, 0.726 and 0.775). Conclusions: Changes in the levels of steroid hormones and lipids could correlate with the elevated chance of CRC. Therefore, assessment of multiple markers might overcome and provide better judgment in patients with CRC.\",\"PeriodicalId\":271947,\"journal\":{\"name\":\"Hormozgan Medical Journal\",\"volume\":\"18 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormozgan Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/hmj.102085\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormozgan Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/hmj.102085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:脂质通常对肿瘤的发生至关重要,而血脂异常与结直肠癌(CRC)的高发病几率相关。类固醇激素如雌激素和黄体酮可以降低患结直肠癌的风险。目的:本研究旨在比较结直肠癌患者和健康对照者的血脂和类固醇激素水平。方法:本研究纳入了2017年至2020年在伊朗萨里Mazandaran癌症中心连续收治的40例成年结直肠癌患者。结直肠癌的诊断基于结肠镜活检和CT扫描。此外,CRC的诊断是基于肿瘤学NCCN临床实践指南。在治疗前进行常规检测时采集血样。每位患者采集外周血5ml。所有患者都签署了这项研究的书面同意书。同时,从同一地区选取40名健康受试者作为常规体检的健康对照,并通过结肠镜筛查和病理检查确认。用比色法定量测定血清TCh和TG水平。用免疫比浊法测定LDL-C和HDL-C。根据试剂制造商的说明,用酶联免疫吸附试验(ELISA)定量测定类固醇激素。采用SPSS软件包(version 21)进行数据分析。结果:在所研究的各项指标中,结直肠癌患者睾酮、FSH和LH水平(平均±SD)(1.85±1.63 ng/ml、15.35±0.13mIU/l、12.42±0.12.16mIU/ml)高于健康对照组(平均±SD)(0.40±0.21ng/ml、6.27±0.50mIU/ml、2.89±0.20mIU/ml, P < 0.05)。亚组结果显示,女性结直肠癌患者睾酮(0.91±1.2ng/l)、卵泡刺激素(19.11±16mIU/ml)、LH(14.49±14mIU/ml)水平均高于健康女性对照组,差异有统计学意义(p = 0.02, 0.00, 0.00)。睾酮、FSH、LH的AUC曲线下面积(图1)为阳性(0.670、0.726、0.775)。结论:类固醇激素和脂质水平的变化可能与结直肠癌发病率升高有关。因此,多种标志物的评估可能会克服并为结直肠癌患者提供更好的判断。
Serum Lipid Profile and Steroid Hormone Levels in Patients with Colorectal Cancer
Background: Lipids are usually crucial to develop tumors, and dyslipidemia is correlated with the high chance of colon and colorectal cancer (CRC). Steroid hormones such as estrogen and progesterone can decrease the risk of colorectal cancer development. Objectives: The present study aimed to compare the serum levels of lipid profile and steroid hormones in patients with CRC and healthy controls. Methods: The present study included 40 consecutive adult patients with CRC in the Mazandaran Cancer Center, Sari, Iran, between 2017 and 2020.The diagnosis of CRC was evaluated based on colonoscopy with biopsy and CT scan. Also, the diagnosis of CRC was based on NCCN clinical practice guidelines in oncology. Blood samples were taken before treatment during routine testing. A 5 mL of peripheral blood was collected from each patient. All patients signed the written consent for the study. Also, a total of 40 healthy subjects were selected as healthy controls from the same area during a routine physical examination, which was also confirmed by screening colonoscopy and pathology. Serum TCh and TG levels were quantitatively determined by the colorimetric method. LDL-C and HDL-C were determined by the turbidimetric immunoassay. Steroid hormones were quantitatively determined by the Enzyme-linked immunosorbent assay (ELISA) according to the reagent manufacturer’s instruction. To analyze data, the SPSS software package (version 21) was applied. Results: Among all the indicators studied, the (mean ± SD) of testosterone, FSH and LH levels was higher (1.85 ± 1.63 ng/ml, 15.35 ± 0.13mIU/l, 12.42 ± 0.12.16mIU/ml) in patients with CRC than (mean ± SD) healthy controls (0.40 ± 0.21ng/ml, 6.27 ± 0.50mIU/ml, 2.89 ± 0.20mIU/ml, P < 0.05), respectively. Also, the results in subgroups showed that the mean testosterone (0.91 ± 1.2ng/l), FSH (19.11 ± 16mIU/ml), LH (14.49 ± 14mIU/ml) levels in the woman patients with CRC was higher than healthy female controls and had more statistical significance (p = 0.02, 0.00, 0.00), respectively. The area under the AUC cure (Figure 1) of the testosterone, FSH, and LH indicates positive test (0.670, 0.726 and 0.775). Conclusions: Changes in the levels of steroid hormones and lipids could correlate with the elevated chance of CRC. Therefore, assessment of multiple markers might overcome and provide better judgment in patients with CRC.